New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 28, 2012
16:10 EDTQGENQIAGEN gains FDA approval to market careHPV test in China
QIAGEN announced that China's State Food and Drug Administration has approved QIAGEN's careHPV Test and instrument platform. The careHPV Test is the first molecular diagnostic to screen for high risk human papillomavirus, or HPV, designed for low-resource clinical settings, such as areas lacking electricity, water or modern laboratory infrastructure. QIAGEN expects to announce the product availability of careHPV in China in January 2013, followed by India later in 2013 and other emerging markets as approvals are received. QIAGEN will introduce the careHPV Test and key data of its performance at the International Papillomavirus, or IPV, conference, starting November 30 in Puerto Rico.
News For QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 12, 2015
09:31 EDTQGENTokai Pharmaceuticals announces collaboration with QIAGEN
Subscribe for More Information
05:36 EDTQGENQIAGEN announces regulatory registration of lung cancer companion diagnostic
Subscribe for More Information
January 11, 2015
15:20 EDTQGENQIAGEN expects to meet 2014 guidance ex-charges
Subscribe for More Information
15:16 EDTQGENQIAGEN to take Q4 charges of $41M for acquisition, restructuring
QIAGEN said that following its acquisition of the Enzyme Solutions Unit from Enzymatics, it will take a business integration and acquisition-related pre-tax charge on operating income in Q4 of approximately $21M, or 6c per share of adjusted diluted EPS, and of which $18M are non-cash items. These charges, which will be excluded from adjusted results, involve actions to reduce overlapping activities and sites, including the closing of the Gaithersburg, Maryland, site. In addition, following a review to further improve efficiency and effectiveness, QIAGEN will now take a restructuring-related pre-tax charge on operating income in Q4 of approximately $26M, or 8 per share, of which $20M are non-cash items. In line with QIAGEN's policy, the restructuring charges, which primarily involve the impairment of various technology-related assets, will not be excluded from adjusted results.
15:12 EDTQGENQIAGEN acquires Enzyme Solutions Unit of Enzymatics
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use